With wider availability of WGS analysis of tumours at diagnosis, WGS data will facilitate the development of patient-specific MRD assays, as well as identifying diagnostic molecular lesions (e.g. EWSR1 translocations in EWS), stratifying molecular features (e.g. MYCN amplification in HR-NB) and identifying targetable lesions (e.g. ALK mutation in HR-NB). Here, MYCN is linked to neuroblastoma.